A Single Arm Phase II Study of the Efficacy, Safety, and Biomarkers of Activity of E7820 plus Cetuximab in Patients with Colorectal Cancer Preceded by a Run-In Study to Determine Safety of the Combination in Advanced Solid Tumors

Trial Profile

A Single Arm Phase II Study of the Efficacy, Safety, and Biomarkers of Activity of E7820 plus Cetuximab in Patients with Colorectal Cancer Preceded by a Run-In Study to Determine Safety of the Combination in Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Cetuximab (Primary) ; E 7820 (Primary)
  • Indications Colorectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 13 May 2016 Planned End Date changed to Apr 2017.
    • 27 Jan 2016 Status changed from completed to active, no longer recruiting reported by ClinicalTrials.gov record.
    • 01 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top